GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are approved for type 2 diabetes and obesity, not Hashimoto's thyroiditis
The following scenarios should be considered for clinical application of microdosing
Studies that have shown the beneficial impact of GLP-1 on endothelial function and microcirculatory integrity in patients with CAD were limited by small sample size and often nonrandomized character
These systems remove guesswork about needle selection and ensure consistent quality
Are triglycerides, cholesterol, and blood pressure improving
Triple Agonist Mechanism: GIP, GLP-1, and Glucagon To appreciate why retatrutide has generated such intense scientific interest, it helps to look at each of the three receptors it targets and how they integrate in metabolic signaling